Want to join the conversation?
$ACET's 4Q16 net sales fell 7.6% to $135.4MM versus 4Q15. Human Health segment sales fell 18.2% due to greater price competition at Rising Pharmaceuticals. Pharmaceutical Ingredients grew 11.3%, driven by rise in sales of Active Pharmaceutical Ingredients sold abroad. Performance Chemicals sales fell 8.6% due to lower sales of specialty chemicals.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.